300 million people affected worldwide 1

Nearly 4% of the world's population is affected by one of more than 80 different autoimmune diseases, the most common of which include type 1 diabetes, multiple sclerosis, rheumatoid arthritis, lupus, Crohn's disease, psoriasis and scleroderma.

Current Treatments 1

Generally, autoimmune disorders cannot be cured but can be made more manageable with medications that suppress or otherwise alter the immune system. Common medications used to treat these disorders include; anti-inflammatory drugs, corticosteroids, immunosuppressants and pain-killing medication.

Psychedelic research currently is in Preclinical

Eleusis, Pilz Biosciecnes and MYND are trying to harness the anti-inflammatory properties of psychedelics. Human trials are yet to take place.

Key Insights

  • Immunity refers to the ability of the body to resist a particular infection or toxin by the action of specific antibodies or sensitized white blood cells. Immunity generally involves the body’s inflammatory response, a major part of the body’s immune system.
  • Research in this particular area of psychedelic science is in its infancy. From animal and in vitro studies, researchers postulate that psychedelics’ potential anti-inflammatory role relates to their ability to block the production/release of pro-inflammatory mediators.
  • Companies including Eleusis, Pilz Biosciences and MYND Life Sciences are currently exploring the possibility of using psychedelics to target inflammation therapeutically.

Psychedelics and Immunitiy

Psychedelics hold promise for treating a range of mental health disorders like depression, anxiety, PTSD and many more. Each of these disorders is complex in nature and are generally characterized by a combination of abnormal thoughts, perceptions, emotions, behaviour and relationships with others [1].

However, despite the various underlying causes and the range of different symptoms of the many mental disorders, they all share one major commonality; they impact people psychologically. Subsequently, psychedelics possess the ability to alleviate the psychological impact people experience, helping them to an overall better quality of life.

The manner in which psychedelics exert their effects remains speculative at best. Nonetheless, as we are progressing through the psychedelic renaissance, researchers are finding that the therapeutic potential of psychedelics knows no limits.

Not only may psychedelics help us to avert an escalating global mental health crisis, but research is also showing that the capabilities of psychedelics are extending into the realm of physical disorders due to their anti-inflammatory properties.

What is Immunity?

Immunity refers to the ability of the body to resist a particular infection or toxin by the action of specific antibodies or sensitized white blood cells. Immunity generally involves the body’s inflammatory response.

The inflammatory response is a major part of the body’s immune system, the complex network of cells and proteins that defend the body against infection. If body tissue is damaged by bacteria, trauma, toxins, heat, or any other cause, the inflammatory response is initiated.

Once the inflammatory cell signalling pathways are initiated, leukocytes, more commonly known as white blood cells, produce cytokines which then induced the inflammatory response [2]. At the tissue level, inflammation is characterized by redness, swelling, heat, pain and loss of tissue function [3].

However, sometimes the body mistakenly perceives its own tissue cells as harmful, leading to aberrant activation of the inflammatory response [4]. In this instance, persisting inflammation can lead to a variety of inflammation-associated disorders such as diabetes, cardiovascular disease and arthritis, amongst other autoimmune disorders.

Unregulated inflammation has also been implicated in neurodegenerative disorders including Alzheimer’s, Parkinson’s and Multiple Sclerosis [5]. The exact causes of these inflammation-associated disorders remain unknown at best. However, risk factors exist and include genetics, being overweight and smoking behaviour [6].

Generally, these autoimmune disorders cannot be cured but can be made more manageable with medications that suppress or otherwise alter the immune system. Common medications used to treat these disorders include; anti-inflammatory drugs, corticosteroids, immunosuppressants and pain-killing medication.

A recent report found that the global autoimmune disease therapeutics market accounted for nearly $109.83 billion in 2017, and is expected to reach $153.32 billion by 2025 [7]. Thus, it is no wonder that people are interested in using the potential of psychedelics to help treat these disorders.

The Potential of Psychedelics

Research in this particular area of psychedelic science is in its infancy. Nonetheless, researchers are postulating this potential role of psychedelics using the limited data that is available.

This hypothesis stems from the ability of psychedelics to bind receptors, such as serotonin and sigma-1 receptors, which have been shown to play crucial roles in numerous immunological processes [8].

How serotonin receptor (5-HT2A) agonists, like psychedelics, could act as anti-inflammatory agents is explored in a review article written by Thomas Flanagan and Charles Nichols. While the studies in the review have predominately been conducted in cellular and animal models, the findings that psychedelics block the production of pro-inflammatory mediators such as TNF-α warrants investigation in human models.

Attilla Szabó and Ede Frecska offer food for thought on the potential of DMT as a ‘biochemical Swiss Army knife’ in neuroinflammation and neuroprotection. Given that DMT has been shown to be a sigma-1 receptor agonist, it has the potential to suppress pro-inflammatory cytokines as well as simultaneously promoting neuroprotective mechanisms. 

A more recent review paper has eloquently summarized what we know about psychedelics and their effect on the immune system. Furthermore, the review details the current state of knowledge regarding the biochemical processes in which psychedelics have been implicated and the potential therapeutic benefits we may incur with further research.

Non-classic psychedelics such as ketamine have also been investigated for their anti-inflammatory properties. A recently published review found that in patients with unipolar and bipolar depression, as well as in animal models of depression, ketamine induces anti-inflammatory effects by decreasing the expression of pro-inflammatory cytokines.

Psychedelic industry and immunity

Given that much of the data which is currently available regarding the anti-inflammatory properties of psychedelics comes from animal models, this particular application of psychedelics is yet to receive significant interest from industry players. Nevertheless, some companies are trying to develop this particular application.

One of the first companies to begin working toward harnessing the therapeutic potential of psychedelics was Eleusis in 2013. The company was co-founded by Shlomi Raz and the aforementioned Charles Nichols, a current Professor of Pharmacology and Experimental Therapeutics at Louisiana State University.

In 2015 and 2016, Eleusis conducted two Phase I studies exploring the safety and efficacy of using lysergic acid diethylamide (LSD) in the context of Alzheimer’s disease (AD). The pathophysiology of AD has been linked to neuroinflammation however, the exact causes remain unknown.

While the trial was conducted in older healthy volunteers, the researchers found that low doses of LSD were well tolerated and their findings support the further clinical development of LSD for the treatment of AD.

The team at Eleusis are also focusing on transforming psilocybin into a safe, effective and affordable treatment for depression in a Phase II trial they have planned. In this trial, researchers will simultaneously focus on clarifying the role of psychedelics, specifically 5-HT2A receptor agonists, as modulators of immune function and make their findings clinically relevant in order to treat inflammatory disorders.

Pilz BioSciecne is another company that are trying to harness the anti-inflammatory properties of psychedelics. The team at Pilz are specifically targeting the role of pro-inflammatory processes in autism spectrum disorder. To do so, Pilz is developing a number of synthetic derivatives of classic psychedelics which they aim to bring to the clinical trial process.

MYND Life Sciences are developing MYND-604 as an oral dosage form of psilocybin for the treatment of major depressive disorder (MDD). The team at MYND are exploring the anti-inflammatory MYND-604 has in people who are depressed. Recently, MYND was awarded a patent for using MYND-604 to treat depression by targeting levels of neuroinflammation.

MYND is collaborating with Michael Smith Laboratories at The University of British Columbia in order to better understand the complex nature of neurological and psychiatric disorders and, in turn, develop the therapeutic application of psychedelics for treating these disorders. The researchers aim to therapeutically target the link between neuroinflammation and mental health disorders using psychedelics.

As research in this field progresses it is likely more companies will enter this space, eventually providing us with a novel viable therapy option in autoimmune and inflammation-associated disorders.


1. World Health Organization. (2019). Mental disorders. Geneva: World Health Organization. https://www.who.int/news-room/fact-sheets/detail/mental-disorders

2. Linlin, C., Dong, H., Cui, H., Fang, J., Zuo, Z., Deng, J., . . . Zhao, L. (2018). Inflammatory responses and inflammation-associated diseases in organs. Oncotarget, 7204-7218. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805548/

3. Takeuchi, O., & Akria, S. (2010). Pattern recognition receptors and inflammation. Cell, 805-20. https://pubmed.ncbi.nlm.nih.gov/20303872/

4. Felman, A. (2020). Everything you need to know about inflammation. Medical News Today. https://www.medicalnewstoday.com/articles/248423

5. Kwon, H., & Koh, S.-H. (2020). Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Translational Neurodegeneration. https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/s40035-020-00221-2

6. Orbai, A.-M. (n.d). What Are Common Symptoms of Autoimmune Disease? Baltimore: Johns Hopkins Medicine. https://www.hopkinsmedicine.org/health/wellness-and-prevention/what-are-common-symptoms-of-autoimmune-disease

7. BioSpace. (2021). Autoimmune Disease Therapeutics Market Value with Status and Outlook 2021 to 2025. BioSpace. https://www.biospace.com/article/autoimmune-disease-therapeutics-market-value-with-status-and-outlook-2021-to-2025/

8. Szabo, A. (2015). Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities. Frontier in Immunology.

Highlighted Institutes

These are the institutes, from companies to universities, who are working on Immunity.

Highlighted People

These are some of the best-known people, from researchers to entrepreneurs, working on Immunity.

Linked Research Papers about Immunity

The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study

Dimethyltryptamine (DMT): a biochemical Swiss Army knife in neuroinflammation and neuroprotection?

Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers

Classic psychedelics do not affect T cell and monocyte immune responses

The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells

Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation

Psychedelics as potent anti-inflammatory therapeutics

Salvia divinorum: from recreational hallucinogenic use to analgesic and anti-inflammatory action

Psychedelic-Inspired Approaches for Treating Neurodegenerative Disorders

Psilocybin Combines Rapid Synaptogenic And Anti-Inflammatory Effects In Vitro

Ketamine’s antidepressant effect is mediated by energy metabolism and antioxidant defense system

First Time View on Human Metabolome Changes after a Single Intake of 3,4-Methylenedioxymethamphetamine in Healthy Placebo-Controlled Subjects

Immunological Effects of Ayahuasca in Humans

The effect of Banisteriopsis caapi (B. caapi) on the motor deficits in the MPTP-treated common marmoset model of Parkinson’s disease

Psychedelic N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine Modulate Innate and Adaptive Inflammatory Responses through the Sigma-1 Receptor of Human Monocyte-Derived Dendritic Cells

Do entheogen-induced mystical experiences boost the immune system? Psychedelics, peak experiences, and wellness

Psychedelics as anti-inflammatory agents

MDMA related neuro-inflammation and adenosine receptors

Hemorheological and metabolic consequences of renal ischemia-reperfusion and their modulation by N,N-dimethyl-tryptamine on a rat model

Ketamine interactions with gut-microbiota in rats: relevance to its antidepressant and anti-inflammatory properties

Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review

Associations between lifetime classic psychedelic use and cardiometabolic diseases

Banisteriopsis caapi, a Forgotten Potential Therapy for Parkinson’s Disease?

Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson’s disease

From Psychiatry to Neurology: Psychedelics as Prospective Therapeutics for Neurodegenerative Disorders

Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms

Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency

Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities